Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 15, 2019 - Issue 8
Submit an article Journal homepage
802
Views
0
CrossRef citations to date
0
Altmetric
Editorial

The complexity of adverse event assessment and counseling for patients on biologic treatment

Stephanie R. Cohena Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USACorrespondence[email protected]
View further author information
,
Adrian Ponaa Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USAView further author information
,
Abigail E. Clinea Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USAView further author information
&
Steven R. Feldmana Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA;b Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA;c Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USAORCID Iconhttps://orcid.org/0000-0002-0090-6289View further author information
ORCID Icon
Pages 809-811 | Received 30 Apr 2019, Accepted 09 Jul 2019, Published online: 12 Jul 2019

References

  • Abreu C, Sarmento A, Magro F. Screening, prophylaxis and counselling before the start of biological therapies: a practical approach focused on IBD patients. Dig Liver Dis. 2017;49(12):1289–1297.
  • Hanley T, Handford M, Lavery D, et al. Assessment and monitoring of biologic drug adverse events in patients with psoriasis. Psoriasis (Auckl). 2016;6:41–54.
  • Kothary N, Diak IL, Brinker A, et al. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol. 2011;65(3):546–551.
  • Garcia-Doval I, Carretero G, Vanaclocha F, et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol. 2012;148(4):463–470.
  • Alatawi YM, Hansen RA. Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf. 2017;16(7):761–767.
  • World Medical Association.World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194.
  • Millum J, Grady C. The ethics of placebo-controlled trials: methodological justifications. Contemp Clin Trials. 2013;36(2):510–514.
  • James S, Rao SV, Granger CB. Registry-based randomized clinical trials–a new clinical trial paradigm. Nat Rev Cardiol. 2015;12(5):312–316.
  • Devine F, Edwards T, Feldman SR. Barriers to treatment: describing them from a different perspective. Patient Prefer Adherence. 2018;12:129–133.
  • Katz MG, Kripalani S, Weiss BD. Use of pictorial aids in medication instructions: a review of the literature. Am J Health Syst Pharm. 2006;63(23):2391–2397.
  • Keyworth C, Nelson PA, Bundy C, et al. Does message framing affect changes in behavioural intentions in people with psoriasis? A randomized exploratory study examining health risk communication. Psychol Health Med. 2018;23(7):763–778.
  • Mansoor LE, Dowse R. Effect of pictograms on readability of patient information materials. Ann Pharmacother. 2003;37(7–8):1003–1009.
  • Abood DA, Black DR, Coster DC. Loss-framed minimal intervention increases mammography use. Womens Health Issues. 2005;15(6):258–264.
  • Davis SA, Feldman SR. An illustrated dictionary of behavioral economics for healthcare professionals. 1 ed. Columbia, SC: CreateSpace Independent Publishing Platform; 2014.
  • ClinicalTrials.gov. 2012 Jun 12 - Identifier NCT01617018 Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatment of Cutaneous Psoriasis (PSOBIOTEQ); 2018 Jul 23. Bethesda, MD: National Library of Medicine. [cited 2019 Jun 19]. Available from: http://clinicaltrials.gov/ct/show/NCT01617018?order=1.
  • ClinicalTrials.gov. 2017 Aug 18- Identifier NCT03254667 LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis; 2018 Apr 10. Bethesda, MD: National Library of Medicine. [cited 2019 Jun 19]. Available from: http://clinicaltrials.gov/ct/show/NCT03254667?order=1.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.